52 completed, 26 unknown, 5 recruiting, 4 not yet recruiting. 92 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 92 | Completed 52, Unknown 26, Recruiting 5, Not yet recruiting 4, Withdrawn 3, Active not recruiting 1, Suspended 1 |
Follow Clarithromycin: new trials by email Literature Review of Clarithromycin trials Research Report on Clarithromycin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety of Vonoprazan-Amoxicillin Dual Therapy Versus Concomitant Quadruple Therapy for H. Pylori Eradication Vonoprazan (Reference), Amoxicillin, Metronidazole - HELICOBACTER PYLORI INFECTIONS | Phase 4 | Recruiting | Ignacio Moratorio | 100 | 2026-08-05 | 2026-11-09 |
| Clinical Trial to Evaluate the Efficacy of Probit-Based Triple Therapy for Helicobacter Pylori Eradication This study aims to evaluate the efficacy and safety of a 14-day triple therapy regimen consisting of Zastaprazan 20 mg, clarithromycin, and amoxicillin for the eradication of Helicobacter pylori. - Helicobacter Infection | Phase 4 | Not yet recruiting | Samsung Medical Center | 103 | 2025-12-01 | 2025-08-14 |
| Comparison of Two Treatment Regimens of Helicobacter Pylori Infection Clarithromycin, Levofloxacin - Helicobacter Pylori Infection | Phase 4 | Not yet recruiting | Rehman Medical Institute - RMI | 156 | 2025-12-01 | 2025-06-15 |
| Tailored Vs. Empirical Helicobacter Pylori Infection Treatment Clarithromycin (mutations in the 23S rRNA gene, A2134G, A2142G and A2142C mutations) and levofloxacin resistance (mutations in the gyrA gene) PCR test, Empirically H. pylori eradication treatment with bismuth quadruple therapy (Pylera®), PPI, amoxicillin 1 g and clarithromycin 500 mg, twice daily, for 10 days - Helicobacter Pylori Infection | Phase 4 | Not yet recruiting | Manuel Coelho da Rocha | 160 | 2025-09-01 | 2024-12-20 |
| Comparison of Omeprazole vs Vonoprazon in Treatment of H Pylori Infection Clarithromycin 500 mg, Amoxicillin 1 g, Omeprazole 40 mg - H Pylori | Phase 4 | Not yet recruiting | Rehman Medical Institute - RMI | 128 | 2025-07-01 | 2025-06-27 |
| Efficacy Comparison of Vonoprazan Combined With Different Antibiotics in Dual Therapy for Helicobacter Pylori Eradication: A Prospective, Randomized Controlled Clinical Trial Vonoprazan, Tetracycline 500mg tid, Minocycline - Gastritis, Indigestion, Helicobacter Pylori Infection, Gastric Cancer, Peptic Ulcer | Phase 4 | Recruiting | Yongquan Shi | 400 | 2025-04-01 | 2025-08-14 |
| Vonoprazan Evaluation Compared to Standard Triple Therapy in Helicobacter Pylori eRadication Vonoprazan 20mg, Esomeprazole 40 mg, Amoxicillin 1 g, Clarithromycin 500 mg - Helicobacter Pylori Infection | Phase 4 | Recruiting | Asian Institute of Gastroenterology, India | 484 | 2025-03-25 | 2025-06-11 |
| Efficacy and Safety of Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CABP) Faropenem, Co-amoxiclav, Clarithromycin 500 mg - Pneumonia, Community-Acquired, Bacterial Pneumonia | Phase 4 | Completed | Dr. Md. Alimur Reza | 129 | 2025-02-20 | 2026-08-04 |
| Efficacy and Safety of Tegoprazan and Minocycline Dual Therapy for Helicobacter Pylori Initial Treatment tegoprazan, Minocycline, bismuth potassium citrate - Helicobacter Pylori Infection Chronic Gastrit | Phase 4 | Active not recruiting | Xijing Hospital of Digestive Diseases | 208 | 2024-11-11 | 2025-07-03 |
| Study on The Efficacy and Safety of Vonoprazan-containing Berberine Triple Therapy in Helicobacter Pylori First-Line Eradication Berberine, Vonoprazan, Amoxicillin - Helicobacter Pylori Infection, Chronic Gastritis | Phase 4 | Completed | Xijing Hospital of Digestive Diseases | 558 | 2024-09-20 | 2025-07-03 |
| Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT) Ceftriaxone 1000 MG, Clarithromycin 500mg, Metronidazole 500 mg - Preterm Premature Rupture of Membrane, Pregnancy, High Risk | Phase 4 | Recruiting | Ohio State University | 56 | 2024-07-18 | 2026-01-27 |
| Study on the Efficacy and Safety of Berberine, Minocycline, Esomeprazole, and Colloidal Bismuth Quadruple Therapy in the Initial Treatment of Helicobacter Pylori. esomeprazole, Bismuth, Amoxicillin - Helicobacter Pylori Infection, Chronic Gastritis | Phase 4 | Unknown | Xijing Hospital of Digestive Diseases | 548 | 2023-11-20 | 2024-09-19 |
| Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy Vonoprazan and Amoxicillin, Lansoprazole, Amoxicillin, Clarithromycin and Metronidazole - Helicobacter Pylori Infection | Phase 4 | Completed | Fu Jen Catholic University Hospital | 337 | 2023-11-14 | 2026-02-17 |
| Immunomodulatory Effect of Macrolides in Naturally Occurring Influenza Virus Infections in the Community Clarithromycin 250 MG, Placebos - Influenza, Human | Phase 4 | Suspended | The University of Hong Kong | 100 | 2023-06-01 | 2022-11-04 |
| Efficacy of Therapy Based on Fecal Molecular Antimicrobial Susceptibility Tests for Helicobacter Pylori Infection Rabeprazole, Colloidal Bismuth Pectin Granules, Amoxicillin - Helicobacter Pylori Infection | Phase 4 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 855 | 2023-03-01 | 2023-05-15 |
| Effects of High-dose Dual Therapy and Bismuth Quadruple Therapy for Helicobacter Pylori Eradication on Intestinal Microecology Esomeprazole, Amoxicillin, Bismuth - Gastritis, Dyspepsia | Phase 4 | Completed | Xijing Hospital of Digestive Diseases | 124 | 2022-12-01 | 2025-07-03 |
| Efficacy and Safety of Dual Therapy as First-line Treatment for Hp Infection Vonoprazan, Rabeprazole, Amoxicillin - Helicobacter Pylori Infection | Phase 4 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 393 | 2022-08-01 | 2023-02-16 |
| Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection susceptibility-guided tailored therapy (Group A), guidelines-recommended empiric therapy (Group B) - Helicobacter Pylori Infection | Phase 4 | Recruiting | National Taiwan University Hospital | 450 | 2022-04-11 | 2026-04-15 |
| Susceptibility-Guided Therapy for Helicobacter Pylori Infection Treatment Esomeprazole, Bismuth potassium citrate, Metronidazole - Helicobacter Pylori Infection | Phase 4 | Withdrawn | Shanghai Zhongshan Hospital | 2022-03-25 | 2026-08-04 | |
| Effectiveness of Minocycline-Containing Bismuth Quadruple Therapy for Helicobacter Pylori Eradication Minocycline hydrochloride capsule, Clarithromycin, Amoxicillin - Helicobacter Pylori Eradication | Phase 4 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 339 | 2022-01-05 | 2022-01-13 |
Showing 20 of 92. Sign in to see all of them.
Dyspepsia (9) · Peptic Ulcer (9) · Gastritis (7) · Helicobacter Infections (6) · Stomach Neoplasms (3) · Community-Acquired Pneumonia (2) · Pneumonia (2) · cyclopia sequence (2) · Asthma (1) · Borrelia Infections (1) · Chorioamnionitis (1) · Community-Acquired Infections (1) · Crohn Disease (1) · Drug-Related Side Effects and Adverse Reactions (1) · Duodenal Ulcer (1)
Xijing Hospital of Digestive Diseases (9) · Shandong University (7) · Shanghai Jiao Tong University School of Medicine (6) · National Taiwan University Hospital (4) · Mackay Memorial Hospital (3) · Second Affiliated Hospital, Zhejiang University, School of Medicine (3) · Shanghai Zhongshan Hospital (3) · Damascus Hospital (2) · Kaohsiung Veterans General Hospital. (2) · Kyungpook National University Hospital (2) · Rehman Medical Institute - RMI (2) · The University of Texas Health Science Center at Tyler (2) · Abdul Wali Khan University Mardan (1) · Al-Azhar University (1) · Alexandra Hospital, Athens, Greece (1)
China (28) · Taiwan (12) · South Korea (5) · United States (4) · Pakistan (3) · Egypt (2) · Greece (2) · Iran (2) · Netherlands (2) · Spain (2) · Syria (2) · Turkey (Türkiye) (2) · Bangladesh (1) · Burma (1) · Denmark (1)
Xiuli Zuo, MD,PhD (5) · Hong Lu, M.D. (4) · Yongquan Shi, Ph. D (4) · Tai-cherng Liou, MD (3) · Li Yanqing, MD, PhD (2) · Taotao Liu, MD (2) · Adrian Canavesi, Endoscopist (1) · Ala' I Sharara, MD (1) · Arnaud Perrier, MD (1) · Bader F Zuberi, FCPS (1) · Bart-Jan Kullberg, Prof., M.D. (1) · Chi-Yang Chang, PhD (1) · Chris J Hawkey (1) · David Y Graham, MD (1) · Dennis KM Ip, MD (1)
PMID 32545856, PMID 20947881, PMID 23158886, PMID 23520311, PMID 23562754, PMID 23665990, PMID 25070099, PMID 25286173, PMID 25574111, PMID 25639278, PMID 26338726, PMID 26338825, PMID 26935876, PMID 27028911, PMID 27769562, PMID 27867688, PMID 28266875, PMID 28456631, PMID 28891138, PMID 29082856, PMID 29138921, PMID 30180998, PMID 30635887, PMID 30734357, PMID 30796143, PMID 30893536, PMID 31024299, PMID 31111585, PMID 31523279, PMID 31590634, PMID 31974914, PMID 32428369, PMID 33089598, PMID 34031759, PMID 35164864, PMID 35505308, PMID 36237565, PMID 37361220, PMID 37479526, PMID 38700630, PMID 39924352, PMID 40007457, PMID 40560185, PMID 40844182, PMID 42069497, PMID 42141850, PMID 42595603
2009 (1)